Decoding 4 Analyst Evaluations For Macrogenics - Macrogenics (NASDAQ:MGNX)

In the last three months, 4 analysts have published ratings on Macrogenics (NASDAQ:MGNX), offering a diverse range of perspectives from bullish to bearish.

The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.

	Bullish	Somewhat Bullish	Indifferent
Total Ratings	2	1	1
Last 30D	0	0	1
1M Ago	0	1	0
2M Ago	1	0	0
3M Ago	1	0	0

In the assessment of 12-month price targets, analysts unveil insights for Macrogenics, presenting an average target of $15.0, a high estimate of $17.00, and a low estimate of $13.00. Surpassing the previous average price target of $9.67, the current average has increased by 55.12%.

Exploring Analyst Ratings: An In-Depth Overview

The analysis of recent analyst actions sheds light on the perception of Macrogenics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
Robert Burns	HC Wainwright & Co.	Raises	Neutral	$14.00	$12.00
Silvan Tuerkcan	JMP Securities	Raises	Market Outperform	$16.00	$10.00
Yigal Nochomovitz	Citigroup	Raises	Buy	$13.00	$7.00
Jonathan Block	Stifel	Maintains	Buy	$17.00	-

Key Insights:

Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Macrogenics. This information provides a snapshot of how analysts perceive the current state of the company.
Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Macrogenics compared to the broader market.
Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Macrogenics's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Macrogenics analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

All You Need to Know About Macrogenics

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Unraveling the Financial Story of Macrogenics

Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.

Revenue Growth: Macrogenics's revenue growth over a period of 3 months has faced challenges. As of 30 September, 2023, the company experienced a revenue decline of approximately -75.09%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.

Net Margin: Macrogenics's net margin excels beyond industry benchmarks, reaching 168.84%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Macrogenics's ROE stands out, surpassing industry averages. With an impressive ROE of 9.6%, the company demonstrates effective use of equity capital and strong financial performance.

Return on Assets (ROA): Macrogenics's ROA excels beyond industry benchmarks, reaching 5.44%. This signifies efficient management of assets and strong financial health.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.18.

The Core of Analyst Ratings: What Every Investor Should Know

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

MGNXMacrogenics Inc

$4.16-0.01%

Overview

Market News and Data brought to you by Benzinga APIs

To add Benzinga News as your preferred source on Google, click here.